Centessa Pharmaceuticals Ltd Business Finance Contracts & Agreements
24 Contracts & Agreements
- Assignment Agreements (4 contracts)
- Contribution Agreements (10)
- Deposit Agreements (1)
- Note Agreements (3)
- Registration Rights Agreements (2)
- Share Agreements (2)
- Stock Agreements (1)
- Underwriting Agreements (1)
- Amendment to Note Purchase Agreement, dated June 23, 2023, by and between the Registrant, the Purchasers party thereto and Cocoon SA LLC (Filed With SEC on August 14, 2023)
- Amendment to Note Purchase Agreement, dated November 7, 2022, by and between the Registrant, the Purchasers party thereto and Cocoon SA LLC (Filed With SEC on March 30, 2023)
- Amendment to Note Purchase Agreement and Waiver, dated February 11, 2022 (Filed With SEC on March 30, 2022)
- Form of Underwriting Agreement (Filed With SEC on May 26, 2021)
- 2021 Share Option Plan and forms of award agreements thereunder (Filed With SEC on May 24, 2021)
- 2021 Employee Share Purchase Plan (Filed With SEC on May 24, 2021)
- Form of Deposit Agreement (Filed With SEC on May 24, 2021)
- Assignment and Bill of Sale, dated December 20, 2017, by and between Advent Private Equity Fund III A, Advent Private Equity Fund III B, Palladio Biosciences, Inc and the other... (Filed With SEC on May 12, 2021)
- Assignment and Bill of Sale, dated November 7, 2017, by and between Healthcare Ventures VII, L.P., and Palladio Biosciences, Inc (Filed With SEC on May 12, 2021)
- Assignment and Bill of Sale, dated June 2017, by and between Perseus-Soros BioPharmaceutical Fund Liquidating Trust and Palladio Biosciences, Inc (Filed With SEC on May 12, 2021)
- Assignment and Bill of Sale, dated February 24, 2017, by and between Care Capital Investments II, LP, Care Capital Offshore Investments II, LP, and Palladio Biosciences, Inc (Filed With SEC on May 12, 2021)
- Stock Purchase Agreement, dated July 26, 2016, by and between Chiesi USA, Inc., Palladio Acquisition Sub, Inc. and Palladio Biosciences, Inc (Filed With SEC on May 12, 2021)
- Registration Rights Agreement by and among the registrant and the Investors listed therein, dated January 29, 2021 (Filed With SEC on May 12, 2021)
- Contribution Agreement, dated December 31, 2020 (as amended), by and between PearlRiver Bio GmbH, United Medicines Biopharma Limited, and the other parties thereto (Filed With SEC on April 21, 2021)
- Contribution Agreement, dated January 23, 2020, by and between Pega-One, United Medicines Biopharma Limited and the other parties thereto (Filed With SEC on April 21, 2021)
- Contribution agreement, dated January 23, 2021, by and between Z Factor Limited, United Medicines Biopharma Limited and the other parties thereto (Filed With SEC on April 21, 2021)
- Contribution agreement, dated January 23, 2021, by and between Orexia Limited, United Medicines Biopharma Limited and the other parties thereto (Filed With SEC on April 21, 2021)
- Contribution agreement, dated January 23, 2021, by and between Morphogen-IX Limited, United Medicines Biopharma Limited and the other parties thereto (Filed With SEC on April 21, 2021)
- Contribution agreement, dated January 23, 2021, by and between LockBody Therapeutics Ltd, United Medicines Biopharma Limited and the other parties thereto (Filed With SEC on April 21, 2021)
- Contribution agreement, dated January 23, 2021, by and between Janpix Limited, United Medicines Biopharma Limited and the other parties thereto (Filed With SEC on April 21, 2021)
- Contribution agreement, dated January 23, 2021, by and between Inexia Limited, United Medicines Biopharma Limited and the other parties thereto (Filed With SEC on April 21, 2021)
- Contribution agreement, dated January 23, 2021, by and between Capella Bioscience LTD, United Medicines Biopharma Limited and the other parties thereto (Filed With SEC on April 21, 2021)
- Contribution agreement, dated January 23, 2021, by and between ApcinteX Limited, United Medicines Biopharma Limited and the other parties thereto (Filed With SEC on April 21, 2021)
- Contingent Value Rights Agreement, dated as of January 23, 2021, by and among the Registrant, Palladio Biosciences, Inc. and the representative of the holders of contingent value... (Filed With SEC on April 21, 2021)
